Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00245414
Status:
COMPLETED
Last Update Posted:
2010-11-17
First Post:
2005-10-27
Brief Title:
Trial of Pegasys in Patients With Chronic Hepatitis C
Sponsor:
Chugai Pharmaceutical
Organization:
Chugai Pharmaceutical
Study Overview
Official Title:
Post-marketing Clinical Trial of Pegasys 180μg for Subcutaneous Injection in Patients With Chronic Hepatitis C General Clinical Study in Interferon IFN-Treated and IFN-untreated Chronic Hepatitis C Patients Except for Those Infected With High Viral Load of Genotype 1b
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy and safety of Pegasys 180μg for subcutaneous sc injection in interferon IFN-treated or IFN-untreated chronic hepatitis C patients except for those infected with genotype 1b of hepatitis C virus HCV and a high viral load 100 KIUmL
In addition this study will explore the efficacy and safety of Pegasys 180μg for sc injection given at 2 different periods between 24 and 48 weeks in IFN-untreated chronic hepatitis C patients
In addition this study will explore the efficacy and safety of Pegasys 180μg for sc injection given at 2 different periods between 24 and 48 weeks in IFN-untreated chronic hepatitis C patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None